In our study, late-stage cancer patients exhibited significantly higher levels of CEA, CA125 and CA15-3 compared with early-stage ones, suggesting that the serum levels of these tumor markers might be more efficient for monitoring advanced tumors than early diagnosis. This evidence concerns the gene CEACAM5 and neoplasm.